Customize your JAMA Network experience by selecting one or more topics from the list below.
To test the influence of vascular endothelial growth factor (VEGF) on normal and ischemic wounds in a noncontractive dermal ulcer standardized model in the rabbit ear and to assay the levels of both VEGF and basic fibroblastic growth factor messenger RNA levels in normal and ischemic wounds at different intervals during the healing process.
Design and Interventions
Dermal ulcers were created in the normal and ischemic ears of 20 anesthetized young female New Zealand white rabbits. Either VEGF 121, VEGF 165 (30 µg per wound), or buffered saline solution alone was applied to each wound and covered. Wounds were harvested at day 7 or 10 and evaluated histologically. Twenty-four similar rabbits were wounded in the same manner and their untreated wounds were harvested at 1, 3, 7, and 10 days after wounding. The wounds were analyzed with reverse transcriptase polymerase chain reaction.
Main Outcome Measures
Histologic specimens were measured for amount of new epithelium and granulation tissue. Reverse transcriptase polymerase chain reaction was used to determine basic fibroblastic growth factor and VEGF messenger RNA expression.
Both isoforms of VEGF improved granulation tissue formation in both normal and ischemic wounds with a magnitude similar to other vulnerary agents tested in the past. Vascular endothelial growth factor application had no effect on new epithelium formation. In contrast to basic fibroblastic growth factor, VEGF messenger RNA levels were induced 4 fold by ischemia alone and 6 fold by wounding in both ischemic and normal wounds.
Vascular endothelial growth factor seems to be more important than basic fibroblastic growth factor during ischemic wound healing. Treatment of ischemic wounds with VEGF improves the deficit in wound healing produced by ischemia.
WOUND HEALING is characterized by an ordered sequence of events in response to injuries that ultimately result in tissue formation, reepithelialization, and scar formation. Angiogenesis is an integral part of this sequence of events and occurs during the proliferative phase of wound healing. It is characterized by new vessel formation and vascular hyperpermeability that improve tissue oxygenation and nutrient delivery and promote cellular and matrix deposition in the wound.1
Several growth factors have been implicated as possible mediators of angiogenesis during wound repair, including transforming growth factor beta-1, tumor necrosis factor α, epidermal growth factor, keratinocyte growth factor, interleukins 1, 6, and 8, basic fibroblastic growth factor (bFGF), platelet-derived growth factor (PDGF),2,3 and most recently, vascular endothelial growth factor (VEGF).4-6 These growth factors have angiogenic properties in vitro and in vivo. Their angiogenic properties have been traditionally categorized as either direct or indirect based on endothelial cell activation and mitogenesis.7,8 Of these, only bFGF, PDGF, and VEGF have been shown to be directly mitogenic to endothelial cells7,9,10; however, it remains unclear which of these growth factors is the most important mediator of the angiogenic phase of healing. This question is of primary clinical importance, since improving the angiogenic response during wound healing using a single growth factor or in combination, may partially reverse the healing deficit observed in ischemic wounds.
Several authors have described possible mechanisms by which these growth factors are angiogenic.7-9 There is evidence that suggests that not only the indirect angiogenic factors, but also bFGF and PDGF, may be acting in vivo through VEGF transcriptional regulation.3,7,11-14 We have previously described the effects of transforming growth factor beta-1, PDGF, and bFGF in both ischemic and nonischemic wound healing.15-17 These 3 growth factors improve wound healing and promote angiogenesis in the rabbit ear dermal ulcer model. The notable exception is bFGF, which failed to improve granulation tissue formation and epithelialization in ischemic wounds despite eliciting a marked local angiogenic response.17
Vascular endothelial growth factor is a heparin-binding dimeric glycoprotein and a member of the PDGF family of growth factors. It has 4 known homodimers of varying size and solubility (121, 165, 184, and 209 kd). The isomers are generated by posttranscriptional splicing of a single VEGF gene.18 Vascular endothelial growth factor receptors have been found primarily in vascular endothelium; however, they are also found in human melanoma cells, HeLa cells, and monocytes.19 In contrast to bFGF, VEGF contains a typical signal sequence, can be secreted by intact cells, and is expressed in a variety of highly vascularized tissues, including the ovary, kidneys, brain, and solid tumors.3,9 Vascular endothelial growth factor has been shown to directly induce mitogenesis and interstitial collagenase transcription in endothelial cells.20 It has also been shown to up-regulate in keratinocytes at the wound edges during wound healing in rat and guinea pig skin.4 In contrast to bFGF, VEGF has potent vascular hyperpermeability effects during wound healing that may enhance the delivery of nutrients to the site of repair.4 More importantly, VEGF transcription has been shown to not only be up-regulated by ischemia both in vitro and in vivo, but also in response to a variety of growth factors and cytokines.3,9 In addition, VEGF messenger RNA (mRNA) is stabilized in response to hypoxia, increasing the availability of VEGF transcripts during ischemic conditions.21-23
The precise role VEGF plays in the wound healing process is unknown; however, given its known biological activity, VEGF could potentially be playing a prominent role in the repair process. In the following set of experiments, we tested the effect of exogenous VEGF 121 or VEGF 165 treatment in both ischemic and nonischemic wounds in the rabbit ear dermal ulcer model. These 2 isomers were chosen since they are readily available and seem to be the most biologically active in vivo. We assayed VEGF and bFGF mRNA levels in normal and ischemic skin and in wounds to highlight any possible differences between these growth factors in their response to an ischemic event.
Materials and methods
Animal wounding and vegf treatment
Young adult female New Zealand white rabbits (New Franken Inc, New Franken, Wis) weighing 2.7 to 3.4 kg, were acclimated and housed under standard conditions and used in all experiments. All surgical procedures were performed under sterile conditions as previously described.24 All animal protocols were approved by Northwestern University Animal Care and Use Committee.
Twenty rabbits were divided into ischemic and nonischemic groups. Rabbits were anesthetized with ketamine hydrochloride (60 mg/kg) and xylazine hydrochloride (5 mg/kg) prior to surgery. In the ischemic group, the ears were made ischemic by dividing the rostral and central arteries and the entire dermal circulation of the ear. Three full-thickness, 6-mm, dermal punches were made down to bare cartilage with the aid of a binocular microscope. In the nonischemic group, 4 wounds were similarly made in each ear. The wounds were treated at the time of wounding with either recombinant VEGF 121, VEGF 165 (30 µg per wound) (AMGEN Corp, Thousand Oaks, Calif), or phosphate-buffered saline solution vehicle. All wounds were covered with an occlusive dressing (Tagaderm; 3M, Minneapolis, Minn) for the duration of the experiment.
Ischemic wounds were harvested at day 10 and nonischemic wounds at day 7 as previously described.25 All wounds were excised, bisected, and fixed in neutral buffered 10% formaldehyde solution (Sigma Chemical Co, St Louis, Mo). The specimens were then dehydrated in graded alcohol and xylene, embedded in paraffin, and sectioned (3 µm), taking care to obtain a cross section as near as possible to the center of the wound.
All slides were stained with hematoxylin-eosin using standard protocols. The stained sections were analyzed under ×40 magnification. All slides were examined by 2 independent observers (C.J.C. and A.S.) with standard light microscopy under ×40 magnification. New granulation tissue formation and new epithelium were measured using a 100-µm lens redicle on the light microscope at ×40 magnification. The redicle was sectioned into 10-µm2 squares, and the area occupied by the tissue was measured.
Rna extraction and competitive reverse transcriptase polymerase chain reaction
After wounding, 24 rabbits were divided into 4 groups as to number of days after wounding: day 1, day 3, day 7 and day 10. All rabbits were wounded as above; however, only 1 ear was made ischemic. All wounds were left untreated and were covered with the occlusive dressing for the duration of the experiment. At the appropriate time, the rabbits were anesthetized and a 7-mm punch biopsy specimen of skin was obtained from each ear to serve as an ischemic and a normal skin control. Granulation tissue was harvested with a 7-mm punch biopsy specimen and immediately immersed in liquid nitrogen for later guanidine thiocyanate/phenol–based reagent to isolate RNA from the sample (TRI Reagent, Cincinnati, Ohio) as previously described.26 Total RNA was pooled from each ear and quantified with a spectrophotometer (Genequant model 80-2103-98; Biochrom, Cambridge, England) prior to complementary DNA (cDNA) conversion. Five micrograms of total RNA was converted to cDNA using Maloney-Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) and random primers (Gibco Biological Research Laboratories, Grand Island, NY) as previously described.27
Rabbit VEGF primers were designed from conserved Genbank sequences (AMGEN Corp). Amplimers obtained with these primers were sequenced to assure the correct target gene was being amplified. The FGF rabbit primers were obtained from a Genbank rabbit sequence (AMGEN Corp). Glutaraldehyde phosphate dehydrogenase rabbit primers were kindly donated by US Surgical Corporation, New Haven, Conn. Reverse transcriptase polymerase chain reaction was performed as previously described.27,28 MIMICS for each primer set were designed as described by Siebert and Larrick.27,28 Serial dilutions of MIMIC and constant concentration of cDNA were coamplified using a polymerase chain reaction. These products were run in a 2% agarose gel, photographed under UV light, and analyzed by densitometry (Imaging Densitometer GS-670; Bio Rad, Richmond, Calif). The ratio of target product to MIMIC was then obtained as previously described.29 Glutaraldehyde phosphate dehydrogenase amplification was used as an external control of the reverse transcriptase reaction, and this was run in all cDNA samples tested. Each reaction was run in duplicate starting from the RNA to the cDNA step.
Effect of exogenous vegf on wound healing
Treatment of rabbit ear wounds with 0.1, 1.0, and 10 µg per wound of either isomer of VEGF had no statistically significant effect (data not shown), although there was a trend with higher doses for 10% to 15% improvement in new granulation tissue formation. Single-dose treatment of rabbit ear wounds with VEGF 121 or VEGF 165 at 30 µg per wound improved granulation tissue formation in both ischemic and nonischemic wounds. Ischemic wounds had 100% and 150% more granulation tissue at day 10 when treated with VEGF 121 and VEGF 165, respectively. Nonischemic wounds had 50% and 70% more granulation tissue at day 10 when treated with VEGF 121 and VEGF 165, respectively. The effect was greater in ischemic wounds using either isomer, and the magnitude of the effect was always greater with VEGF 165 (Figure 1). Neither VEGF isomer had an effect on new epithelium formation (Figure 2). Figure 3 shows a representative histological specimen.
New granulation tissue formation in response to 30 µg per wound of vascular endothelial growth factor (VEGF) in nonischemic (A) and ischemic (B) wounds. Note the difference in scale between the 2 graphs.
New epithelium tissue formation in response to 30 µg per wound of vascular endothelial growth factor (VEGF) in nonischemic (A) and ischemic (B) wounds. Note the difference in scale between the 2 graphs. No significant differences were found.
Representative histological samples of each group. Top, Ischemic control group. Bottom, Ischemic wound treated with vascular endothelial growth factor 165. The single arrow points to new epithelium and the double arrow, granulation tissue.
EFFECT OF ISCHEMIA AND WOUNDING ON bFGF AND VEGF mRNA LEVELS
To control for the reverse transcriptase step in our polymerase chain reaction protocol, every cDNA sample was assayed for glutaraldehyde phosphate dehydrogenase expression.27,29 We found no significant difference in glutaraldehyde phosphate dehydrogenase expression in any of the cDNA samples used (Figure 4). Ischemia up-regulated VEGF mRNA expression 3- to 5-fold over nonischemic skin. The effect was seen as early as 1 day following the onset of ischemia and lasted through the duration of the experiment with a trend toward normalization (Figure 4, B). Wounding the skin up-regulated VEGF mRNA expression 6- to 7-fold, irrespective of whether the wound was ischemic. This effect was also seen at day 1 after wounding and persisted for 10 days after wounding (Figure 5). Basic fibroblastic growth factor expression was not significantly induced by ischemia, in fact there was a 2-fold reduction of bFGF mRNA levels in ischemic skin with a trend toward normalization by day 10 after wounding. Wounding alone increased bFGF mRNA levels less than 2-fold over normal skin in both ischemic and nonischemic wounds (Figure 6).
A, Induction of vascular endothelial growth factor messenger RNA levels in response to ischemia. The y-axis is folded over nonischemic skin (n= 8 for each day, P<.001 for all days). B and C, Induction of vascular endothelial growth factor messenger RNA levels in response to wounding. B, Panel shows a nonischemic wound. C, Panel shows an ischemic wound. The y-axis is folded over nonischemic skin (n= 8 for each day, P<.001 for all days).
Induction of glutaraldehyde phosphate dehydrogenase messenger RNA levels in response to ischemia and wounding. The y-axis is folded over nonischemic skin (n=8 for each day, P<.001 for all days).
Induction of basic fibroblastic growth factor messenger RNA levels in response to ischemia and wounding. The y-axis fold over nonischemic skin is increased (n=4 for each day). The only significant difference in this data is the fold increase in wounded tissue vs ischemic unwounded skin at days 3 and 7 (P<.05).
During wound healing an ordered sequence of events takes place that promotes the repair of injured tissues. This cascade of events is triggered by injury and ultimately leads to tissue regeneration, matrix deposition, and scar formation. Angiogenesis is a critical component of the wound healing response, with several growth factors potentially mediating the angiogenic response.
We have previously shown that bFGF, PDGF-BB, and transforming growth factor beta-1 have angiogenic properties in healing wounds and also promote granulation tissue formation, matrix deposition, and reepithelialization through different mechanisms.15-17 Of these, bFGF and PDGF have a direct mitogenic effect on the endothelial cell and are considered to have direct angiogenic properties.7 We have also shown with exhaustive experiments that bFGF improves wound healing in nonischemic wounds, but fails to do so in ischemic wounds.16,17 Thus, the role of bFGF in impaired wound healing remains controversial. Basic FGF seems to improve wound healing in nonischemic models of impaired healing such as diabetic mice and steroid-treated animals30,31; however, a large clinical trial of bFGF in leg ulcers was stopped because no therapeutic effect was detected.32 In 1995, Richard et al33 in 1995 concluded that topical application of bFGF had no advantage over placebo for healing chronic neuropathic diabetic ulcers of the foot. It seems that bFGF may not be effective in impaired models of healing where ischemia is the culprit of the impairment. In light of these data, VEGF may be a more important regulator of angiogenesis and may help to promote wound healing in ischemic wounds. As shown by others, we were also able to detect a 2-fold decrease in bFGF mRNA levels in response to ischemia, an observation that may provide clues as to why bFGF fails to enhance wound healing in ischemic wounds despite improved angiogenesis, and it suggests that bFGF is not the prime mediator of angiogenesis in ischemic conditions.7,34 We have also previously observed that bFGF regained biological activity within ischemic wounds when the rabbits were treated with hyperbaric oxygen.17 These findings imply that oxygen-dependent signaling mechanisms may be required for bFGF activity in hypoxic wounds, and they highlight the potential importance of VEGF as a hypoxia-inducible factor during wound healing.
Vascular endothelial growth factor has biological properties that make it a more attractive modulator during ischemic wound healing than either bFGF or PDGF. Vascular endothelial growth factor mRNA transcription is induced by a variety of growth factors and cytokines. We have shown that VEGF mRNA transcription is not only induced by ischemia in rabbit skin but is also induced to a greater extent by tissue injury. The levels of VEGF mRNA were higher in wounded tissue (6- to 8-fold), irrespective of the tissue oxygen levels. Vascular endothelial growth factor is considered an important regulator of physiologic and pathologic angiogenesis and our data suggest that VEGF may also be an important modulator of ischemic wound healing.21,34
Exogenous VEGF improved granulation tissue formation in both ischemic and nonischemic wounds with a magnitude similar to other previously described vulnerary agents.15-17,25,35 This effect was dose dependent, since doses of 0.1, 1.0, and 10 µg per wound with either isomer had no effect (data not shown). These data were in accordance with prior experiments done in a rat incisional model when neither VEGF 121 nor VEGF 165 improved breaking strength at day 7 after wounding with doses of 10 and 20 µg per wound (data not shown).36
All rabbit wounds treated with doses of either VEGF 121 or VEGF 165, of 30 µg per wound showed a notable increase over controls in the amount of granulation tissue formation. As expected, the magnitude of the effect was doubled in ischemic wounds. The fact that exogenous VEGF still had an effect on rabbit ear wounds despite maximal transcriptional up-regulation implies that either endogenous VEGF levels are not enough to saturate all VEGF receptors or exogenous VEGF has a local autoinductive effect on its own receptors at the wound site. Vascular endothelial growth factor receptors have been found to be up-regulated during wound healing37 and have been shown to be up-regulated in the rat lung in response to ischemia.38,39 Receptor up-regulation may account for the increased effect of exogenous VEGF in ischemic wounds. Recent data from our laboratory suggest that receptor regulation may be more important than growth factor regulation during wound healing.29
Increases in angiogenesis alone cannot entirely explain the observed improvement in granulation tissue, since bFGF fails to promote healing in ischemic wounds despite marked angiogenesis.40 Among the other known biological properties of VEGF, vascular hyperpermeability in the wounded tissue may play a more prominent role during the healing process than previously described. Vascular hyperpermeability improves the efficiency of plasma protein delivery and cellular migration into the area of injury and is not a biological property of bFGF.4,8,14 Moreover, the endothelial cell is known to secrete a host of biologically active growth factors and cytokines that may be released in response to VEGF and not bFGF. These 2 observations may explain the improvement in wound healing in ischemic wounds seen with VEGF treatment and clearly lacking with exogenous bFGF despite increased angiogenesis with both growth factors.
Even though most of the VEGF in wounds appears to be derived from dermal keratinocytes at the wound edge, VEGF did not notably affect epithelium formation in either ischemic or nonischemic wounds.4,5 Unlike bFGF, which has a direct effect on dermal fibroblasts (the primary source of keratinocyte growth factor in the wound), VEGF affects only the endothelial cell that is not a keratinocyte growth factor–producing cell. This may explain in part the lack of effect seen with exogenous VEGF treatment in new epithelium formation.
We found that VEGF 165 was more potent than VEGF 121 in all parameters measured regardless of tissue ischemia. Although no biological differences between the 4 VEGF isoforms have been described, differences in their receptor-binding ability and their capability to interact with extracellular membrane components have been demonstrated.19,41 The different bioactivity between the isomers may be due in part to the ability of heparan sulfates in the extracellular matrix to sequester VEGF 165, a heparin-binding isomer, and keep it active in the tissue for a longer period than VEGF 121, which does not readily bind heparin.
Our results indicate that VEGF is an important vulnerary agent, and a key regulator of angiogenesis during wound healing. Furthermore, these results suggest that the endothelial cell is playing a more prominent role during the wound healing process than simply mitogenesis. Conceivably VEGF, by also mediating vascular hyperpermeability in the tissue and promoting the secretion of biologically active growth factors and cytokines from the endothelial cell, has an important influence on the cascade of events necessary for normal and effective wound repair.
This work was supported in part by grant GM-41303, from the National Institutes of Health, Bethesda, Md (Dr Mustoe).
Presented at the Wound Healing Society Meeting, Minneapolis, Minn, May 1995, and Boston, Mass, June 1996.
Corresponding author: Thomas A. Mustoe, MD, Division of Plastic and Reconstructive Surgery, 707 E Fairbanks Ct, Suite 811, Chicago, IL 60611.
Corral CJ, Siddiqui A, Wu L, Farrell CL, Lyons D, Mustoe TA. Vascular Endothelial Growth Factor Is More Important Than Basic Fibroblastic Growth Factor During Ischemic Wound Healing. Arch Surg. 1999;134(2):200–205. doi:10.1001/archsurg.134.2.200
Coronavirus Resource Center
Create a personal account or sign in to: